The objective of the current study is to investigate the efficacy, safety and tolerability of
Linagliptin (BI 1356) (5 mg or 10 mg / once daily) compared to placebo given for 12 weeks and
voglibose for 26 weeks as mono therapy in patients with type 2 diabetes mellitus with
insufficient glycaemic control. Furthermore, long-term safety is evaluated with an extension
treatment to 52 weeks.